Dr. Laura Soucek obtained a degree in biological sciences from the Sapienza University of Rome (1996). She continued her studies as a graduate student there at the Study Center for Nucleic Acids in the Department of Genetics and Molecular Biology investigating the role of Myc in cancer and Myc-related cancer therapeutics and ascertained her PhD (2001). As co-Director of the Preclinical and Translational Research Program and Head of the Models of Cancer Therapies Laboratories at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Dr. Soucek has continued her work as an ICREA research professor leading her research lab in search of Myc-related cancer therapies.
Dr. Soucek is a member of the Scientific Advisory Board, bringing more than twenty years of research and preclinical pharmaceutical development experience to Radyus. As founder and CEO of Peptomyc S.L., a company she started to develop cancer therapeutics using anti-Myc cell penetrating peptides, Dr. Soucek’s experience leading a research laboratory, her roles in preclinical and translational scientific research, and development of the Myc inhibitor, Omomyc, are crucial to our work at Radyus.
Dr. Soucek is a key opinion leader in Myc biology and Myc inhibition. Dr. Soucek developed the most well-characterized Myc inhibitor to date, Omomyc: the first Myc inhibitor to successfully pass Phase I clinical trial. Omomyc is now proceeding to Phase 1b/II studies. Dr. Soucek received a Ph.D. in Genetics and Molecular Biology from the Sapienza University of Rome where her research focused on the role of Myc and Myc derivatives in apoptosis, cancer, and cancer therapeutics.
She has published over 60 peer-reviewed articles on a wide variety of topics, including: the role of oncogenes in cancer, cancer therapy, tumor microenvironments, carcinogenic potential of environmental chemical mixtures, personalized cancer medicine, undruggable cancer targets, tumor cell self-renewal, pharmacokinetics, inflammation, translational medicine, and phase I dose escalation studies of Myc inhibitors. By combining her extensive laboratory research and leadership experience with her entrepreneurial endeavors, Dr. Soucek seeks to enhance development of therapeutic interventions targeting Myc and cancer with Radyus Research.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
